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Abstract: In this study, 7 new isoxazole compounds (8-14) were synthesized from the cyclization of chalcone compounds (1-7) containing different functional groups with hydroxylamine hydrochloride in alkaline medium. Tyrosinase and antioxidant properties of 8-14
were investigated. IC50 values for the tyrosinase enzyme inhibition of compounds 8, 11, 12, and 13 were varied between 61.47 ± 3.46 and
188.52 ± 5.85, while compounds 9, 10 and 14 did not show any inhibition effect. The antioxidant properties of 8-14 were investigated by
DPPH and CUPRAC methods. Compound 12 showed the best DPPH radical scavenging activity (SC50: 40.21 ± 2.71), while 12 and 13
had shown the greatest Cupric ion reducing effect as 1.233 ± 0.015 and 1.245 ± 0.019 mg TEAC/mg, respectively. As a result, the change
of functional groups in the synthesized compounds caused a significant difference in the biological properties of 8-14.
Key words: Isoxazole, tyrosinase inhibition, antioxidant activity

1. Introduction
The isoxazole and its derivatives are an important intermediate for the synthesis of new chemicals in medicinal chemistry,
which have been increased in last decades. Isoxazole nucleus had shown a wide spectrum of biological activity. Easy
synthesis of isoxazole ring has been as an object of interest for the scientist from research group all over the world. The
synthesis of isoxazole compounds have resulted in multiple corresponding antibacterial drugs in the market (Sulfisoxazole,
Flucloxacillin, Dicloxacillin, Leflunomide, Risperidone, Oxacillin, Sulfamethoxazole, and Cloxacillin) and there are many
patent related with isoxazole [1]. Leflunomide has been approved for the management of the signs and symptoms of active
rheumatoid arthritis (RA) to improve physical function. Sulfisoxazole has been approved for the treatment of severe,
repeated, or long-lasting urinary tract infections by inhibiting the enzyme dihydropteroate synthetase. Risperidone has
been approved for the treatment of schizophrenia in adults [1]. 1,3-Dipolar cycloaddition of α, β-unsaturated ketone or
1,3-diketone is a widely used method for the synthesis of isoxazole [2]. One of the substituted isoxazole synthesis described
using oxime of a ketone [3]. Although there are many methods were reported for the synthesis or modification of the
isoxazole ring [1–9]. Isoxazoles play a fundamental role in the synthesis of numerous biologically active drugs such as
antimicrobial, antiviral, anticancer, immunomodulatory, antiinflammatory, antiplatelet, antithrombotic, antitriglyceride,
antidiabetic, analgesic, anticonvulsant, and anti-Alzheimer agents [2], pesticides and insecticides [10–11]. Thus, the
synthesis of novel isoxazole derivatives remains a main focus of medicinal research. In this work, the synthesis and
biological activities of a new series of isoxazole analogues with a substituted two aromatic rings still needed and are
reported here.
2. Experimental
2.1. Material and methods
Solvents (n-hexane, ethyl alcohol, and diethyl ether), aldehydes and ketone compounds (2/3/4-methoxyacetophenone,
3/4-hydroxyacetophenone, 2,4-dimethoxy-benzaldehyde, 2,5-dimethoxybenzaldehyde, 2,3,4-trimethoxybenzaldehyde,
benzaldehyde, pyridine-2-carbaldeyde, and pyridine-4-carbaldeyde), 1,1-diphenyl-2-picrylhydrazil (DPPH), kojic acid and
any used reagent were purchased from by Sigma-Aldrich, Fluka or Merck unless otherwise stated.
1
H and 13C NMR spectra were obtained on a Bruker 400 MHz NMR spectrometer (400 MHz for 1H, 100 MHz for 13C),
using TMS as an internal standard. CDCl3 and DMSO-d6 were used as NMR solvents. 13C and APT spectra were adjusted
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according to deutero solvent peaks. Chemical shifts were expressed in δ (ppm), and coupling constants (J) were reported in
hertz (Hz). ACD NMR program was used for the interpretation of spectra. FT-IR spectra were taken using the Perkin-Elmer
1600 (ATR) (4000–400 cm–1) spectrophotometer. Melting points were determined using the Thermo-var apparatus fitted
with a microscope. Normal phase silica gel (230–400 mesh) was used in vacuum column chromatography (VLC). TLC was
carried out on Silica gel 60 F254, and the spots were visualized by UV lamp (254 nm and 366 nm) or spraying with 20% H2SO4
and heating.
2.1. General procedure for the synthesis of compounds 1-14.
The synthesis of known chalcone compounds (1-7) was carried out using the Claisen-Schmidt condensation [12,13]. A
mixture of chalcone (1-7) (10 mmol) and hydroxylamine hydrochloride (15 mmol) in ethyl alcohol (30 mL) was refluxed for
12 h in presence of 40% KOH (5 mL) [1–9]. The reaction mixture was controlled by TLC then cooled, poured into crushed ice
and extracted with diethyl ether (30 mL × 3). Solvent was evaporated to give crude products which were chromatographed
by column chromatography using increased polarity of n-hexane then ether mixture to give compounds 8-14 in the range of
45%–63% yield, respectively.
Compound 8 (3-(2-methoxyphenyl)-5-(2,3,4-trimethoxyphenyl)isoxazole): Yield: 63%, m.p. = 102–103 oC, FT-IR (cm–
1
):1589 (C=C, aromatic ring),1606 (C=N), 2940 (=CH), 1H-NMR (δ, ppm, DMSO-d6): 3.97, 3.98 (s, 12 H, -OCH3), arH:[6.80-6.87 (m,1H), 7.04–7.15 (m, 2H), 7.42–7.50 (m,1H), 7.69–7.75 (m,1H), 7.91–7.97 (m,1H)], 7.25 (s,1H, isoxazole-H4),
APT-NMR (100 MHz, DMSO-d6): 61.04, 60.67, 56.11, 55.61 (4x -OCH3), 103.35 (isoxazole-C4), ar-C [107.78 (CH), 115.25
(C),115.51 (CH), 118.54 (C), 120.93 (CH), 122.53 (CH), 129.65 (CH), 131.04 (CH), 142.65 (C), 151.27(C), 155.10 (C),
157.32 (C), 160.93 (isoxazole-C3), 165.35 (isoxazole-C5), ]. LC-TOF-MS: (m/z, %) [M+Na]+: 364.1159 (100), calc. 364,1187.
Supplementary data are in Figures S1–S4.
Compound 9 (3-(4-methoxyphenyl)-5-(2,4-dimethoxyphenyl)isoxazole): Yield: 45%, m.p. = 93–94 oC, FT-IR (cm–1):1594
(C=C, aromatic ring),1613 (C=N), 3058, 3006, 2987 (=CH), 1H-NMR (δ, ppm, DMSO-d6): 3.90 (s, 6H, -OCH3), 4.00 (s, 3H,
-OCH3), ar-H:[ 6.60–6.66 (m, 2H), 6.94–6.98 (m, 2H), 7.82–7.98 (m, 3H)], 7.03 (s,1H, isoxazole-H4), APT-NMR (100 MHz,
DMSO-d6): 55.39, 55.56, 55,64 (3 x -OCH3), 98.92 (isoxazole-C4), ar-C [99.66 (CH), 106.12 (CH), 109.95(C), 114.21 (2CH),
122.26 (C), 128.24 (2CH), 128.84 (CH), 157.61(C), 160.80 (C), 162.26 (C)], 162.58 (isoxazole-C3), 166.26 (isoxazole-C5),.
LC-TOF-MS: (m/z, %) [M+H]+: 312.1235 (100), calc. 312.1222, [M+Na]+: 334.1059 (70), calc. 334.1049. Supplementary data
are in Figures S5–S8.
Compound 10 (3-(3-hydroxyphenyl)-5-(phenyl)isoxazole): Yield: 62%, m.p. = 230–231 oC, FT-IR (cm–1):1605 (C=N),
2962, 2836 (=CH), 3193, 3484 (-OH), 1H-NMR (δ, ppm, DMSO-d6): ar-H: [6.94 (d, 1H, J=6.8 Hz), 7.35–7.38 (m, 2H), 7.54
(d, 4H, J=8.0 Hz), 7.93 (d, 2H, J=6.4 Hz )], 7.31(s,1H, isoxazole-H4), 9.21 (phenolic,-OH) (s, 1H), APT-NMR (100 MHz,
DMSO-d6): 99.00 (isoxazole-C4), ar-C [112.50 (CH), 116.92 (CH), 118.07 (CH), 127.06 (2 CH), 128.42 (C), 129,61 (C),
129.61 (2 CH), 130.76 (CH), 130.96 (CH), 158.40 (C)], 163.03 (isoxazole-C3), 170.29 (isoxazole-C5). LC-TOF-MS: (m/z, %)
[M+H]+: 238.0856 (100), calc. 238.0844. Supplementary data are in Figures S9–S12.
Compound 11 (3-(3-hydroxyphenyl)-5-(2,4-dimethoxyphenyl)isoxazole): Yield: 60%, m.p. = 168–169 oC, FT-IR (cm–1):
1572(C=C, aromatic ring), 1608 (C=N), 2940, 3010, 3007 (=CH), 3256 (-OH), 1H-NMR (δ, ppm, DMSO-d6): 3,85 (s, 3H,
-OCH3), 3.98 (s, 3H, -OCH3) ar-H:[ 6.71 (d, 1H, J=8.8 Hz), 6.90 (d, 1H, J=7.2 Hz), 7.14 (s,1H), 7.30-7.36 (m,3H), 7.81 (d, 1H,
J=8.8 Hz)], 6.75 (s,1H, isoxazole-H4), 9.76 (phenolic,-OH) (s, 1H), APT-NMR (100 MHz, DMSO): 56.33, 55.99 (2 x -OCH3)
, 99.24 (isoxazole-C4), ar-C [100.22 (CH), 106.48 (CH), 108.99 (C), 113.49 (CH), 117.59 (CH), 118.00 (CH), 128.56 (CH),
130.49 (C),130.63 (CH), 157.99 (C), 158.27(C), 162.79 (C)], 162.82 (isoxazole-C3), 166.56 (isoxazole-C5). LLC-TOF-MS:
(m/z, %) [M+H]+: 298.1074, calc. 298.1080. Supplementary data are in Figures S13–S16.
Compound 12 (3-(4-hydroxyphenyl)-5-(2,5-dimethoxyphenyl)isoxazole): Yield: 65%, m.p. = 176–178 oC, , FT-IR (cm–
1
):1575(C=C, aromatic ring), 1603 (C=N), 3061 (=CH), 3479 (-OH), 1H-NMR (δ, ppm, DMSO-d6): 3.76 (s, 3H,-OCH3), 3.84
(s, 3H,-OCH3), ar-H:[ 6.95 (d, 2H, J=8.8 Hz), 7.04–7.07 (m, 1H),7.33 (d, 1H, J=3.2 Hz) , 7.16 (s, 1H), 7.76 (d, 2H, J=8.4 Hz)],
10.1 (phenolic,-OH) (s, 1H), 7.11 (m,1H, isoxazole -H4), APT-NMR (100 MHz, DMSO-d6): 55.94 (-OCH3), 56.60 (-OCH3),
99.86 (isoxazole-C4), ar-C [114.00 (CH), 114.06 (CH), 116.43 (2CH), 117.10 (CH), 127.85 (2CH),118.39 (C), 118.66 (C),
151.69 (C), 153.61(C), 159.84 (C)], 160.45 (isoxazole-C3), 169.67 (isoxazole-C5), LC-TOF-MS: (m/z, %) [M+H]+: 298.1065
(100), calc. 298.1080. Supplementary data are in Figures S17–S20.
Compound 13 (3-(3-methoxyphenyl)-5-(2-pyridinyl)isoxazole): Yield: 58%, m.p. = 98 oC, FT-IR (cm–1): 1568 (C=C,
aromatic ring), 1582 (C=N), 2962, 3049, 3084 (C=C), 1H-NMR (δ, ppm, DMSO-d6): 3.35 (s, 3H,-OCH3), ar-H:[ 7.10 (d, 1H,
J=7.6 Hz), 7.45–7.56 (m, 4H), 8.0 (d, 1H, J=7.6 Hz), 8.07 (d, 1H, J=7.6 Hz), 8.76 (s,1H)], 7.65 (s,1H,isoxazole-H4), APT-NMR
(100 MHz, DMSO-d6): 55.89 (-OCH3), 99.89 (isoxazole-C4), ar-C [111.22 (CH), 117.13 (CH), 118.40 (CH), 121.86 (CH),
125.66 (CH), 128.39 (C), 130.98 (CH), 138.04 (CH), 148.06 (C), 150.40 (CH), 160.23(C)], 164.06 (isoxazole-C3), 170.36
(isoxazole-C5), LC-TOF-MS: (m/z, %) [M+H]+: 253.0990 (100), calc. 253.0890. Supplementary data are in Figures S21–S24.

748

FANDAKLI / Turk J Chem
Compound 14 (3-(4-methoxyphenyl)-5-(4-pyridinyl)isoxazole): Yield: 55%, m.p. = 141–143 oC , FT-IR (cm–1): 1573
(C=C, aromatic ring), 1610 (C=N), 2967, 3019, 3112 (=CH), 1H-NMR (δ, ppm, DMSO-d6): 3.83(s, 3H,-OCH3), ar-H:[7.09–
7.11 (d, 2H, J=7.6 Hz), 7.78 (d, 2H, J=7.6 Hz), 7.82 (d, 2H, J=6.4 Hz), 8.78 (d, 2H, J=6.4 Hz)], 7.80 (s,1H, isoxazole-H4),
APT-NMR (100 MHz, DMSO-d6): 55 (-OCH3), 102 (isoxazole-C4), ar-C [116 (2CH), 119 (2CH), 121 (C), 128 (2CH), 134
(C), 152 (2CH), 162 (C)], 164 (isoxazole-C3), 168 (isoxazole-C5). LC-TOF-MS: (m/z, %) [M+H]+: 253.0977 (100), calc.,
253.0890, [M+Na]+: 275.0805 (60), calc. 275.0825. Supplementary data are in Figures S25–S28.
2.3. Biological activities
2.3.1. Antioxidant activity
2.3.1.1. Cupric ion reducing (CUPRAC) method
The capacity of 8-14 compounds to reduce cupric ions was established as it was described before [14]. A reaction mixture
was prepared by mixing a volume of CuCl2 (0.250 mL, 10 mM), neocuproine (0.250 mL, 7.5 mM in ethanol) and NH4Ac
buffer (0.250 mL, 1 M, pH 7.0) with standard/compound solutions at different concentrations. SA blank was prepared by
adding sample solution to premixed reaction mixture CuCl2. The absorbances of the blank and sample were read at 450
nm after a 30-min incubation at room temperature. The absorbance of the blank was subtracted from that of the sample.
CUPRAC activity was expressed as equivalents of trolox (mg TEAC/mg compound).
2.3.1.2. DPPH free radical scavenging method
The DPPH free radical scavenging activities of 8-14 compounds were determined using the method described before [15].
Alcoholic solution of DPPH (1 mL, 0.1 M in methanol) was mixed with 8-14 compound solutions prepared in DMSO.
The absorbance was noted at 517 nm after incubation in the dark for 50 min. DPPH gives a purple color in methanol. This
color is decayed by antioxidant. So reduction in the absorbance indicates DPPH• scavenging activity. Trolox was used as
standard radical scavenger and values were expressed as SC50 (µg compound per mL), the concentration of the samples
that causes 50% scavenging of DPPH radical.
2.3.2. Tyrosinase inhibition
The mushroom tyrosinase inhibition assay was carried out according previously reported method. A total of 100 µL of
100 mM phosphate buffer (pH 6.8), 20 µL of 250 U/mL mushroom and compounds 8-14 (5 µL) were prepared in 96 well
plate [16,17]. After 10 min of a preincubation period at room temperature, the enzymatic reaction was initiated with the
addition of l-DOPA (3 mM, 20 µL) as substrate. The absorbance was read at 475 nm. The compound concentration giving
50% inhibition of tyrosinase activity was determined by interpolation of concentration-response curves. Kojic acid was
used as a positive control. The extract concentration giving 50% (IC50) of the original tyrosinase activity was determined.
3. Results
3.1. Synthesis
The synthetic procedure of the target compounds was shown in Figure. Commercially available different aromatic ketone
with aldehydes using NaOH were yielded known chalcones (1-7) [18–24] through the Claisen–Schmidt condensation
[12,13] which then were condensed with hydroxylamine hydrochloride in alkaline medium to give their corresponding
isoxazole by intermolecular cycloaddition reaction (Figure) [25]. All new compounds (8-14) were characterized by 1H
NMR, 13C/APT NMR, FT-IR, and LC-TOF/ MS (Supplementary data are in Figures S1–S28). Then these compounds were
screened for their tyrosinase enzyme inhibition and antioxidant properties.
Isoxazole is an azole with an oxygen atom next to the nitrogen. Isoxazole rings are found in some natural products
and a number of drugs such as ibotenic acid, COX-2 inhibitor valdecoxib, furoxan, cloxacillin, dicloxacillin, and
flucloxacillin. The synthetic androgenic steroid danazol also has an isoxazole ring. The synthesis of substituted isoxazoles
are well developed in literature to possess significant biological activities. In the literature, Kang et al. [26] described the
synthesis of a series of new isoxazole derivatives showed potent antibacterial properties against different gram-positive and

1

Figure. Synthetic scheme for the isoxazole derivatives (8-14).
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gram-negative organisms. Lamani et al. [27] reported the synthesis of a new series of benzisoxazolyl imidazothiadiazoles
and evaluated their antibacterial potential. Yamuna et al. [28] also described a synthesis and biological properties of
isoxazolo pyrimidocyclohepta[b]indoles, the best activity against Mycobacterium tuberculosis strain H37Rv were reported
for an isoxazole derivative with MIC value 3.12 mg/mL. Another group of isoxazole derivatives is a series of (1,4-phenylene)
bis(arylsulfonylisoxazoles) synthesized by Lavanya et al. [29] by 1,3-dipolar cycloaddition. Sharp et al. [30] described the
properties of another isoxazole Hsp90 inhibitor. Kamal et al. [31] also reported the synthesis of 3,5-diaryl isoxazole linked
with quinazolinone and assayed for their anticancer activity. There are many manuscript related with the synthesis and
biological evaluation of isoxazoles [1–9].
3.2. Biological activities
3.2.1. Tyrosinase activity of compounds 8-14
The activities on tyrosinase of synthesized compounds 8-14 were performed according to a modified method with Kojic
acid as positive control [17, 32]. The activity effects of 8-14 were summarized in Table 1. As shown in Table 1, among the
synthesis compounds 8, and 11 -13 showed good to moderate activating effect on tyrosinase. The potencies of compound
8 (with the value of IC50 = 66.74 ± 3.96 µg/mL), 11 (IC50 = 61.47 ± 3.46 µg/mL), 12 (IC50 = 91.41 ± 4.15 µg/mL) and 13 (IC50
= 188.52 ± 5.85 µg/mL) were lower to the positive control kojic acid, of which IC50 was 3.2 ± 0.29 µg/mL. The position,
number and nature of the substituent on benzene and pyridine rings were varied in order to identify the most appropriate
group. The compounds with 3-hydroxy and 2,4-dimethoxy (11) showed higher activity compared to with 2-methoxy
and 2,3,4-trimethoxy (8), 4-hydroxy and 2,5-dimethoxy (12), and 3-methoxy and 4-pyridinyl (13), which suggested that
the strong electron donating group and the number of methoxy may be favorable to enhance the activity. However, the
activity dropped rapidly when the less methoxy substituted and the benzene on isoxazole was replaced by pyridine, which
suggested that benzene was fundamental for the activity [25].
Synthetic and natural tyrosinase inhibitors are promising therapeutic agents for skincare and cosmetic products.
Tyrosinase is the key enzyme in the melanogenesis pathway, responsible for the formation of melanin pigment. The most
common target for inhibiting the melanogenesis pathway is the direct inhibition of the catalytic activity of tyrosinase,
and the most widely used hypopigmented agents are tyrosinase inhibitors [17]. Tyrosinase inhibitors, which can inhibit
melanin biosynthesis, are currently used in various hyperpigmentation and cosmetic products to control freckle formation
[32]. Kojic acid is a fungal metabolite that exhibits inhibitory activity against tyrosinase. Kojic acid is often used as a
positive control to discover new tyrosinase inhibitors [33,34].
In the literature, a series of novel isoxazole chalcone derivatives have been synthesized, and evaluated for
tyrosinase activities. Among them, 1-(4-((3-phenylisoxazol-5-yl)methoxy)phenyl)-3-phenylprop-2-en-1-one was
reported as a potent tyrosinase activator [35]. In another study, isoxazole chalcone was reported that they inhibit
the monopenolase activity of fungal tyrosinase [25]. In another work, novel 2-
(3,
5-
disubstituted isoxazolyl)
-
1,
5-
benzodiazepines has been reported and those hybrid compounds exhibited moderate to significant antityrosinase activities
[36]. The tyrosinase inhibitory activity of the natural curcuminoid analogs on both L-tyrosine and DOPA substrates were
reported. The isoxazole analog showed IC50 values of 8.3, μM, and were 20.9-fold more active than kojic acid [37]. Thus,
they showed awareness of tyrosinase activities according to the substitution difference of isoxazole compounds.
3.2.2. Antioxidant activity of compounds 8-14
Antioxidant properties of synthesized compounds 8-14 were made according to CUPRAC and DPPH methods [14,
38–39] as seen in Table 2. The highest CUPRAC values of isoxazole compounds (8-14) were 1.245 ± 0.019, 1.233.33 ±
0.015, and 1.189.33 ± 0.021 (μg/mL trolox/gram DW) in compounds 13, 12, and 14, and the lowest DPPH values for
compounds 11 and 10 were found to be 0.584 ± 0.011 mg/mL and 0.789 ± 0.009 mg/mL, respectively. When the activities
of all compounds according to CUPRAC and DPPH were examined, it was seen that compound 13 for CUPRAC, and
compound 11 for DPPH were the most effective antioxidant compounds. When looking at the substitution positions of
these compounds, it has been found that they are generally more effective when they are substituted at the 3-position
phenyl ring which is substituted at the C-3 position of isoxazole. Isoxazole having 3-hydroxy and 3-methoxy at the phenyl
group which are attached at the C-3 position of isoxazoles (11 and 13) showed the greatest activity due to the electron
donation and formation of phenoxy radical.
Cancer is one of the leading causes of mortality in the world. There has been a lot of effort to discover new anticarcinogenic
agents that allow treatment with fewer side effects. Isoxazole is the anticancer agent. A series of isoxazole-carboxamide
derivatives were reported and evaluated for their antioxidant activity in DPPH assay. One of the compound was reported
the most active as antioxidant agent (IC50 = 7.8 ± 1.21 μg/mL) compared with Trolox (IC50 2.75 μg/mL) [40]. Antioxidant
activity of isoxazole-based chalcones were reported [41]. A novel series of indolyl isoxazole derivatives were synthesized
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Table 1. Tyrosinase inhibition of compounds 8-14.
No

Tyrosinase (IC50 µg/mL)

8

66.74 ± 3.96

9

No inhibition

10

No inhibition

11

61.47 ± 3.46

12

91.41 ± 4.15

13

188.52 ± 5.85

14

No inhibition

Kojic acid

3.2 ± 0.29

Table 2. Antioxidant (CUPRAC and DPPH) activities of
compounds 8-14.
No

DPPH, SC50 (µg/mL)

CUPRAC (mg TEAC/mg)

8

61.42 ± 1.41

1.156 ± 0.026

9

71.96 ± 2.36

0.856 ± 0.013

10

65.65 ± 1.69

0.789 ± 0.009

11

81.52 ± 3.66

0.584 ± 0.011

12

40.21 ± 2.71

1.233 ± 0.015

13

57.32 ± 2.12

1.245 ± 0.019

14

54.41 ± 2.87

1.189 ± 0.021

Trolox

5.56 ± 0.85

-

and their antioxidant activity were evaluated [42]. The substituted isoxazole derivatives displayed antioxidant activity
[43]. The disubstituted and trisubstituted isoxazoles have been reported to exhibit antioxidant activity [44]. Antioxidant
activity of novel functionalized isoxazole derivatives were reported and among them 5-amino-3(pyridine-4-yl)isoxazole4-carbonitrile was highly significant [45]. As seen in the literature, compounds having isoxazole ring with different
substituents had shown very different biological activities. In this study, tyrosinase and antioxidant activities of 7 different
isoxazole compounds, which are not found in the literature, were reported.
4. Conclusion
In summary, this article is based on synthesized new isoxazole derivatives which display wide spectrum of biological
potential such as anticancer, antiinflammatory, antimicrobial, antiviral, antiplatelet, immunomodulatory, antithrombotic,
antitriglyceride, antidiabetic, analgesic, anticonvulsant, anti-Alzheimer agents, pesticides and insecticides. The heterocyclic
moiety being so versatile in nature offers the medicinal chemist to explore more about the data mentioned in this article,
which will be a great help to prospective researches working in this area for further studies. Thus, the synthesis of new
isoxazole is still needed. Compounds 11 and 8 could be used as new potential tyrosinase inhibitor and 13 as antioxidant
agent. It may be concluded that isoxazole moiety is an important heterocyclic compound as an essential constituent of
large number of marketed drugs. Isoxazole compounds have a great potential to be explored for the development of new
chemical compounds to treat a variety of clinically important diseases.
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